

Masanori Abe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6777142/publications.pdf>

Version: 2024-02-01

131
papers

2,317
citations

218381

26
h-index

288905

40
g-index

133
all docs

133
docs citations

133
times ranked

2524
citing authors

#	ARTICLE	IF	CITATIONS
1	Super high-flux membrane dialyzers improve mortality in patients on hemodialysis: a 3-year nationwide cohort study. CKJ: Clinical Kidney Journal, 2022, 15, 473-483.	1.4	11
2	Combination of once-weekly haemodialysis with peritoneal dialysis is associated with lower mortality compared with peritoneal dialysis alone: a longitudinal study. CKJ: Clinical Kidney Journal, 2021, 14, 1610-1617.	1.4	12
3	Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia. Clinical and Experimental Nephrology, 2021, 25, 1-8.	0.7	5
4	Association between plasma aldosterone and markers of tubular and glomerular damage in primary aldosteronism. Clinical Endocrinology, 2021, 94, 920-926.	1.2	7
5	Assessment of the accuracy of an intermittent scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study. Therapeutic Apheresis and Dialysis, 2021, 25, 586-594.	0.4	15
6	Primary aldosteronism and obstructive sleep apnea. Medicine (United States), 2021, 100, e25049.	0.4	5
7	Transcriptional Suppression of Diabetic Nephropathy with Novel Gene Silencer Pyrrole-Imidazole Polyamides Preventing USF1 Binding to the TGF- β 1 Promoter. International Journal of Molecular Sciences, 2021, 22, 4741.	1.8	3
8	Significance of Levocarnitine Treatment in Dialysis Patients. Nutrients, 2021, 13, 1219.	1.7	14
9	Tuberculosis Relapse in the Epididymis After the Completion of Nine Months of Anti-Tuberculosis Chemotherapy in a Patient with Poorly Controlled Diabetes Mellitus. Therapeutics and Clinical Risk Management, 2021, Volume 17, 463-470.	0.9	0
10	High-performance dialyzers and mortality in maintenance hemodialysis patients. Scientific Reports, 2021, 11, 12272.	1.6	4
11	Dialyzer Classification and Mortality in Hemodialysis Patients: A 3-Year Nationwide Cohort Study. Frontiers in Medicine, 2021, 8, 740461.	1.2	6
12	Mobility performance impacts mortality risk in community-dwelling healthy older adults in Japan: a prospective observational study. Aging Clinical and Experimental Research, 2021, 33, 2511-2517.	1.4	6
13	Increased expression of acyl-CoA oxidase 2 in the kidney with plasma phytanic acid and altered gut microbiota in spontaneously hypertensive rats. Hypertension Research, 2021, 44, 651-661.	1.5	6
14	TWIST1 transcriptionally upregulates complement 3 in glomerular mesangial cells from spontaneously hypertensive rats. Hypertension Research, 2021, , .	1.5	2
15	Association between the use of exchange devices for peritoneal dialysis fluids and peritonitis incidence: A nationwide cohort study. Peritoneal Dialysis International, 2021, , 089686082110515.	1.1	1
16	Dialyzer surface area is a significant predictor of mortality in patients on hemodialysis: a 3-year nationwide cohort study. Scientific Reports, 2021, 11, 20616.	1.6	4
17	Adrenal Venous Sampling for Subtype Diagnosis of Primary Hyperaldosteronism. Endocrinology and Metabolism, 2021, 36, 965-973.	1.3	8
18	Acute esophageal necrosis after cellulitis in an obese patient with diabetes mellitus. Journal of Diabetes Investigation, 2020, 11, 250-252.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Mobility performance among healthy older adults eligible for long-term care in Japan: a prospective observational study. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 1931-1937.	1.4	8
20	Method of Determining Pyrrole-Imidazole Polyamide in Rat Plasma Using Ultra-Fast Liquid Chromatography-Ultraviolet Spectrometry. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 124-128.	0.6	0
21	Role of complement 3 in the pathogenesis of hypertension. <i>Hypertension Research</i> , 2020, 43, 255-262.	1.5	12
22	Annual dialysis data report 2018, JSDT Renal Data Registry: dialysis fluid quality, hemodialysis and hemodiafiltration, peritoneal dialysis, and diabetes. <i>Renal Replacement Therapy</i> , 2020, 6, .	0.3	26
23	Seasonal variation in hydration status among community-dwelling elderly in Japan. <i>Geriatrics and Gerontology International</i> , 2020, 20, 904-910.	0.7	7
24	Calculation of expected remaining lifetime of dialysis patients in Japan. <i>Renal Replacement Therapy</i> , 2020, 6, .	0.3	2
25	Glycated albumin and hemoglobin A1c levels and cause-specific mortality by patients' conditions among hemodialysis patients with diabetes: a 3-year nationwide cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001642.	1.2	9
26	Effect of Adult Weight Gain on Non-Alcoholic Fatty Liver Disease and Its Association with Anthropometric Parameters in the Lean Japanese Population. <i>Diagnostics</i> , 2020, 10, 863.	1.3	1
27	Application of explainable ensemble artificial intelligence model to categorization of hemodialysis-patient and treatment using nationwide-real-world data in Japan. <i>PLoS ONE</i> , 2020, 15, e0233491.	1.1	13
28	Prevalence of Zinc Deficiency in Japanese Patients on Peritoneal Dialysis: Comparative Study in Patients on Hemodialysis. <i>Nutrients</i> , 2020, 12, 764.	1.7	15
29	<p>A Single Episode of Hypoglycemia as a Possible Early Warning Sign of Adrenal Insufficiency</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 147-153.	0.9	2
30	Role of complement 3 in renin generation during the differentiation of mesenchymal stem cells to smooth muscle cells. <i>American Journal of Physiology - Cell Physiology</i> , 2020, 318, C981-C990.	2.1	10
31	Contribution of TGF- β 1 and Effects of Gene Silencer Pyrrole-Imidazole Polyamides Targeting TGF- β 1 in Diabetic Nephropathy. <i>Molecules</i> , 2020, 25, 950.	1.7	18
32	Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report. <i>Clinical Diabetes and Endocrinology</i> , 2020, 6, 1.	1.3	18
33	Hyponatremia Associated with Prophylactic Low-Dose Trimethoprim during Systemic Corticosteroid Therapy for AQP4-Positive Optic Neuritis in a Diabetic Patient. <i>Antibiotics</i> , 2020, 9, 201.	1.5	5
34	Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1219-1240.	0.9	3
35	Effect of cosyntropin during adrenal venous sampling on subtype of primary aldosteronism: analysis of surgical outcome. <i>European Journal of Endocrinology</i> , 2020, 182, 265-273.	1.9	11
36	Inverse Correlation Between Grip Strength and Serum Phosphorus: A Retrospective Observational Study in Japanese Elderly with Poorly Controlled Type 2 Diabetes. <i>Geriatrics (Switzerland)</i> , 2020, 5, 33.	0.6	3

#	ARTICLE	IF	CITATIONS
37	MON-198 Cosyntropin Stimulation on Adrenal Venous Sampling Obscure Surgically Curable Primary Aldosteronism. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
38	Identification of Clock Genes Related to Hypertension in Kidney From Spontaneously Hypertensive Rats. <i>American Journal of Hypertension</i> , 2020, 33, 1136-1145.	1.0	5
39	Title is missing!. , 2020, 15, e0233491.		0
40	Title is missing!. , 2020, 15, e0233491.		0
41	Title is missing!. , 2020, 15, e0233491.		0
42	Title is missing!. , 2020, 15, e0233491.		0
43	Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 713-720.	2.4	68
44	Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function. <i>Hypertension</i> , 2019, 74, 630-638.	1.3	36
45	FP716 EFFICACY OF LEVOCARNITINE SUPPLEMENTATION IN IMPROVING LEAN BODY MASS AND PHYSICAL FUNCTION IN PATIENTS ON HEMODIALYSIS: A RANDOMIZED CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
46	Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Peritoneal Dialysis. <i>Nutrients</i> , 2019, 11, 2645.	1.7	11
47	Preclinical Study of DNA-Recognized Peptide Compound Pyrrole-Imidazole Polyamide Targeting Human TGF- β 1 Promoter for Progressive Renal Diseases in the Common Marmoset. <i>Molecules</i> , 2019, 24, 3178.	1.7	10
48	Correlation between Aortic Calcification Score and Biochemical Parameters in Hemodialysis Patients. <i>Contributions To Nephrology</i> , 2019, 198, 40-51.	1.1	3
49	<p>Retention of aberrant cortisol secretion in a patient with bilateral macronodular adrenal hyperplasia after unilateral adrenalectomy</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 337-342.	0.9	3
50	Predictors of outcomes in patients on peritoneal dialysis: A 2-year nationwide cohort study. <i>Scientific Reports</i> , 2019, 9, 3967.	1.6	18
51	Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study. <i>Scientific Reports</i> , 2019, 9, 3320.	1.6	21
52	Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Hemodialysis. <i>Blood Purification</i> , 2019, 47, 38-44.	0.9	15
53	Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia. <i>Internal Medicine</i> , 2019, 58, 251-257.	0.3	2
54	Adiponectin Receptor gene Polymorphisms are Associated with Kidney Function in Elderly Japanese Populations. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 328-339.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Visualization of Blood Glucose Fluctuations Using Continuous Glucose Monitoring in Patients Undergoing Hemodialysis. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 413-414.	1.3	11
56	The adrenal gland circadian clock exhibits a distinct phase advance in spontaneously hypertensive rats. <i>Hypertension Research</i> , 2019, 42, 165-173.	1.5	14
57	Efficacy of L-carnitine supplementation for improving lean body mass and physical function in patients on hemodialysis: a randomized controlled trial. <i>European Journal of Clinical Nutrition</i> , 2019, 73, 293-301.	1.3	19
58	9. ζ ³ -â°ζ—... (DM). <i>Nihon Toseki Igakkai Zasshi</i> , 2019, 52, 781-787.	0.2	0
59	Diet Therapy for Chronic Kidney Disease. <i>Journal of the Nihon University Medical Association</i> , 2019, 78, 237-241.	0.0	0
60	Glycated albumin versus hemoglobin A1c and mortality in diabetic hemodialysis patients: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1150-1158.	0.4	29
61	A case of apolipoprotein A-I deficiency due to carboxyl-terminal truncation. <i>Journal of Clinical Lipidology</i> , 2018, 12, 511-514.	0.6	5
62	Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report. <i>Journal of Diabetes Investigation</i> , 2018, 9, 223-225.	1.1	6
63	Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 591-596.	0.7	1
64	Development and validation of subtype prediction scores for the workup of primary aldosteronism. <i>Journal of Hypertension</i> , 2018, 36, 2269-2276.	0.3	49
65	FP655EFFECTS OF DIALYZER MEMBRANE MATERIALS ON SURVIVAL IN CHRONIC HEMODIALYSIS PATIENTS: A 2-YEAR COHORT STUDY FROM THE ANNUAL SURVEY OF THE JAPANESE RENAL DATA REGISTRY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i265-i265.	0.4	0
66	Involvement of complement 3 in the salt-sensitive hypertension by activation of renal renin-angiotensin system in spontaneously hypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1747-F1758.	1.3	22
67	Effects of Levocarnitine Treatment on the Cardiac Function in Hemodialysis Patients. <i>Internal Medicine</i> , 2018, 57, 3503-3505.	0.3	5
68	Rate of the "œburnt-out diabetes" phenomenon in patients on peritoneal dialysis. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 254-262.	1.1	7
69	Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients. <i>Nephron</i> , 2018, 140, 161-168.	0.9	8
70	Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 681-688.	2.4	19
71	Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2018, 47, 406-414.	1.4	32
72	Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 469-472.	0.9	34

#	ARTICLE	IF	CITATIONS
73	Is there a "burnt-out diabetes" phenomenon in patients on hemodialysis?. <i>Diabetes Research and Clinical Practice</i> , 2017, 130, 211-220.	1.1	27
74	Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice. <i>Journal of Pharmacological Sciences</i> , 2017, 134, 29-36.	1.1	20
75	Plasma <scp>adrenocorticotrophic hormone</scp> but not aldosterone is correlated with blood pressure in patients with aldosterone-producing adenomas. <i>Journal of Clinical Hypertension</i> , 2017, 19, 280-286.	1.0	3
76	Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia. <i>CardioRenal Medicine</i> , 2017, 7, 188-197.	0.7	16
77	High-Performance Membrane Dialyzers and Mortality in Hemodialysis Patients: A 2-Year Cohort Study from the Annual Survey of the Japanese Renal Data Registry. <i>American Journal of Nephrology</i> , 2017, 46, 82-92.	1.4	32
78	Scoring system for the diagnosis of bilateral primary aldosteronism in the outpatient setting before adrenal venous sampling. <i>Clinical Endocrinology</i> , 2017, 86, 467-472.	1.2	26
79	Efficacy and Safety of Pregabalin for the Treatment of Neuropathic Pain in Patients Undergoing Hemodialysis. <i>Clinical Drug Investigation</i> , 2017, 37, 95-102.	1.1	10
80	Effect of dialyzer membrane materials on survival in chronic hemodialysis patients: Results from the annual survey of the Japanese Nationwide Dialysis Registry. <i>PLoS ONE</i> , 2017, 12, e0184424.	1.1	52
81	Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-9.	1.0	12
82	Glycated Albumin versus Glycated Hemoglobin as a Glycemic Indicator in Diabetic Patients on Peritoneal Dialysis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 619.	1.8	20
83	SP379 EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i216-i216.	0.4	1
84	Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 244-252.	1.1	13
85	Taurine and magnesium supplementation enhances the function of endothelial progenitor cells through antioxidation in healthy men and spontaneously hypertensive rats. <i>Hypertension Research</i> , 2016, 39, 848-856.	1.5	26
86	Subtype prediction in primary aldosteronism: measurement of circadian variation of adrenocortical hormones and 24-h urinary aldosterone. <i>Clinical Endocrinology</i> , 2016, 84, 814-821.	1.2	13
87	Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 260-270.	2.1	57
88	Best Practice for Diabetic Patients on Hemodialysis 2012. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 40-66.	0.4	64
89	Unusual Manifestation of Graves' Disease: Ventricular Fibrillation. <i>European Thyroid Journal</i> , 2015, 4, 207-212.	1.2	11
90	Systematic implantation of dedifferentiated fat cells ameliorated monoclonal antibody 1-22-3-induced glomerulonephritis by immunosuppression with increases in TNF-stimulated gene 6. <i>Stem Cell Research and Therapy</i> , 2015, 6, 80.	2.4	13

#	ARTICLE	IF	CITATIONS
91	Oral Zinc Supplementation Reduces the Erythropoietin Responsiveness Index in Patients on Hemodialysis. <i>Nutrients</i> , 2015, 7, 3783-3795.	1.7	61
92	Randomized Controlled Trial of Darbepoetin $\hat{\pm}$ Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. <i>International Journal of Molecular Sciences</i> , 2015, 16, 30181-30189.	1.8	6
93	A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1235-1247.	0.9	5
94	DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice. <i>Contributions To Nephrology</i> , 2015, 185, 98-115.	1.1	20
95	Association of restless legs syndrome with oxidative stress and inflammation in patients undergoing hemodialysis. <i>Sleep Medicine</i> , 2015, 16, 941-948.	0.8	34
96	Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, e8-e10.	1.1	4
97	Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 159-164.	1.0	25
98	Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 421-427.	0.6	9
99	Haemodialysis-induced hypoglycaemia and glycaemic disarrays. <i>Nature Reviews Nephrology</i> , 2015, 11, 302-313.	4.1	122
100	Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection. <i>Hypertension Research</i> , 2015, 38, 804-806.	1.5	8
101	Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial. <i>Nutrients</i> , 2014, 6, 5992-6004.	1.7	31
102	Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. <i>Heart and Vessels</i> , 2013, 28, 442-452.	0.5	7
103	L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. <i>Heart and Vessels</i> , 2013, 28, 480-489.	0.5	19
104	Mineral Metabolic Abnormalities and Mortality in Dialysis Patients. <i>Nutrients</i> , 2013, 5, 1002-1023.	1.7	36
105	International Normalized Ratio Decreases After Hemodialysis Treatment in Patients Treated With Warfarin. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 60, 502-507.	0.8	5
106	Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria. <i>Hypertension Research</i> , 2012, 35, 874-881.	1.5	16
107	Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. <i>Hypertension Research</i> , 2011, 34, 935-941.	1.5	26
108	Effects of Lipid-Lowering Therapy with Rosuvastatin on Kidney Function and Oxidative Stress in Patients with Diabetic Nephropathy. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 1018-1028.	0.9	88

#	ARTICLE	IF	CITATIONS
109	Relationship Between Erythropoietin Responsiveness, Insulin Resistance, and Malnutrition-Inflammation-Atherosclerosis (Mia) Syndrome in Hemodialysis Patients with Diabetes. <i>International Journal of Artificial Organs</i> , 2011, 34, 16-25.	0.7	34
110	Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. <i>Endocrine Journal</i> , 2011, 58, 663-674.	0.7	19
111	Characterization of Insulin Adsorption Behavior of Dialyzer Membranes Used in Hemodialysis. <i>Artificial Organs</i> , 2011, 35, 398-403.	1.0	38
112	A case of femoral hemorrhage in a patient with microscopic polyangiitis with low levels of myeloperoxidase-antineutrophil cytoplasmic autoantibody. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 414-418.	0.7	3
113	Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice. <i>Current Drug Metabolism</i> , 2011, 12, 57-69.	0.7	119
114	Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. <i>Hypertension Research</i> , 2011, 34, 268-273.	1.5	44
115	Comparison of Sustained Hemodiafiltration with Acetate-Free Dialysate and Continuous Venovenous Hemodiafiltration for the Treatment of Critically Ill Patients with Acute Kidney Injury. <i>International Journal of Nephrology</i> , 2011, 2011, 1-8.	0.7	24
116	Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. <i>Endocrine Journal</i> , 2010, 57, 579-586.	0.7	15
117	Comparison of Sustained Hemodiafiltration With Continuous Venovenous Hemodiafiltration for the Treatment of Critically Ill Patients With Acute Kidney Injury. <i>Artificial Organs</i> , 2010, 34, 331-338.	1.0	57
118	Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 169-176.	0.9	26
119	Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1027-1037.	1.9	14
120	Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1611-1620.	0.9	21
121	Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. <i>Hypertension Research</i> , 2009, 32, 270-275.	1.5	33
122	Antiproteinuric and Blood Pressure-Lowering Effects of a Fixed-Dose Combination of Losartan and Hydrochlorothiazide in Hypertensive Patients with Stage 3 Chronic Kidney Disease. <i>Pharmacotherapy</i> , 2009, 29, 1061-1072.	1.2	11
123	Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1285-1303.	1.5	5
124	Clinical Evaluation of Pneumonia-associated Rhabdomyolysis With Acute Renal Failure. <i>Therapeutic Apheresis and Dialysis</i> , 2008, 12, 171-175.	0.4	8
125	Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis. <i>Diabetes Research and Clinical Practice</i> , 2008, 80, 432-438.	1.1	13
126	Plasma insulin and C-peptide concentrations in diabetic patients undergoing hemodialysis: Comparison with five types of high-flux dialyzer membranes. <i>Diabetes Research and Clinical Practice</i> , 2008, 82, e17-e19.	1.1	16

#	ARTICLE	IF	CITATIONS
127	Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes?. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 482-483.	2.0	46
128	A Case Report of Acute Renal Failure and Fulminant Hepatitis Associated With Edaravone Administration in a Cerebral Infarction Patient. <i>Therapeutic Apheresis and Dialysis</i> , 2007, 11, 235-240.	0.4	21
129	Plasma Insulin is Removed by Hemodialysis: Evaluation of the Relation Between Plasma Insulin and Glucose by Using a Dialysate With or Without Glucose. <i>Therapeutic Apheresis and Dialysis</i> , 2007, 11, 280-287.	0.4	46
130	Evaluation of the Hemodialysis-induced Changes in Plasma Glucose and Insulin Concentrations in Diabetic Patients: Comparison Between the Hemodialysis and Non-hemodialysis Days. <i>Therapeutic Apheresis and Dialysis</i> , 2007, 11, 288-295.	0.4	33
131	The clinical efficacy of maxacalcitol for secondary hyperparathyroidism in hemodialysis patients: response of whole-PTH and biochemical bone markers. <i>Nihon Toseki Igakkai Zasshi</i> , 2003, 36, 1423-1429.	0.2	0